Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
-$0.04 today
- Market cap
- $694.94M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
Volume 4.62M
Average 2.47M
PRME Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Prime Medicine, Inc.NASDAQ: PRME
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $393K fell 93.5% year over year, behind the +227.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 30.1% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.
Context
- Financing cash flow amounted to 3271.0% of revenue in FY2025, down 3295.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -93.5% toward the trailing-twelve-month pace of +227.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 151.51M USD
- Year-over-year change
- -22.6%
- 4-year CAGR
- -13.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 151.51M | -22.6% |
| FY2024 | 2024-12-31 | 195.88M | +29804.7% |
| FY2023 | 2023-12-31 | 655K | -99.6% |
| FY2022 | 2022-12-31 | 181.49M | -32.6% |
| FY2021 | 2021-12-31 | 269.28M | — |
Financing Cash Flow vs competitors
How PRME compares with its peers on the latest reported figures
- PRME's LTM Mar 2026 financing cash flow of $145.91M is the 3rd largest of the 7 companies compared; the peer median is $76.67M.
- Its year-over-year change of +227.5% is the 2nd highest of 7, against a peer median of +40.5%.
- Financing cash flow amounts to 3616.9% of revenue for PRME, versus a peer median of 108.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $719.96M | +120.5% | +122.7% | 2860.1% | |
| LTM Mar 2026 | $165.06M | +31.3% | -31.7% | 249.7% | |
| LTM Mar 2026 | $145.91M | +227.5% | -5.8% | 3616.9% | |
| LTM Jun 2026 | $107.69M | -77.5% | +62.4% | 69.0% | |
| LTM Mar 2026 | $45.65M | +8746.7% | +378.4% | — | |
| LTM Mar 2026 | $41.91M | -23.0% | +215.9% | 108.3% | |
| LTM Mar 2026 | $7.05M | +49.8% | +31.2% | 62.9% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PRME) | $76.67M | +40.5% | +92.5% | 108.3% | |
Competitors are the stored peer set for PRME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| Deferred Income Tax | (624K) | (964K) | (279K) | 0 | 0 |
| Stock-Based Compensation | 1.75M | 6.46M | 13.91M | 26.07M | 29.27M |
| Change in Working Capital | 31.18M | (35.4M) | 2.65M | 31.08M | (5.34M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.19M | 2.46M | 9.14M | (5.26M) | 996K |
| Other Working Capital | 29.99M | (37.86M) | (6.49M) | 36.33M | (6.34M) |
| Other Non-Cash Items | 98.42M | 17.68M | 11.79M | 9.75M | 9.27M |
| Operating Cash Flow | (34.08M) | (131.83M) | (165.41M) | (122.87M) | (162.56M) |
| Capital Expenditures | (4.15M) | (16.1M) | (8.72M) | (7.29M) | (4.53M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (81.98M) | (123.34M) | (104.95M) | (129.45M) | (205.41M) |
| Sales of Investments | 13M | 93M | 132.56M | 204.2M | 101.18M |
| Other Investing Activities | (496K) | (665K) | (170K) | 1M | 0 |
| Investing Cash Flow | (73.63M) | (47.1M) | 18.71M | 68.46M | (108.76M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 270.36M | 185.32M | 655K | 170.14M | 139.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.09M) | (3.82M) | 0 | 25.74M | 12M |
| Financing Cash Flow | 269.28M | 181.49M | 655K | 195.88M | 151.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 161.57M | 2.57M | (146.05M) | 141.47M | (119.82M) |
| Free Cash Flow | (38.23M) | (147.92M) | (174.14M) | (130.16M) | (167.1M) |
Prime Medicine, Inc.
NASDAQ:PRME
Intrinsic Alpha fair value
Locked
Current Price
$3.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.